Going it alone: possible outcomes for life sciences


With the two-year Brexit negotiations underway, life sciences companies and their lawyers will be watching closely to see how their businesses and IP will be affected. LSIPR reports with views from the UK, France and Germany.

The UK is aiming to leave the EU by March 2019. This means a lot of things are set to change in the next two years.

Since the UK government started its withdrawal process in late March, the UK and the rest of the EU life sciences sectors have been trying to secure their IP positions.

According to Alasdair Poore, partner at Mills & Reeve in the UK, one of the aspects which will change in the life sciences area is research.

Brexit, negotiations, Life Sciences, Alasdair Poore, Mills & Reeve, UPC,